MSB 0010445

Drug Profile

MSB 0010445

Alternative Names: EMD 521873; MSB0010445; NHS-IL2; NHS-IL2-LT; Selectikine

Latest Information Update: 25 Mar 2017

Price : $50

At a glance

  • Originator EMD Serono; Merck Serono
  • Class Antineoplastics; Cytokines; Immunoconjugates; Recombinant fusion proteins
  • Mechanism of Action Interleukin-2 receptor agonists
  • Orphan Drug Status

    Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.

    No
  • On Fast track

    Fast track status is assigned by the US FDA so therapies with the potential to address unmet needs can move faster through development.

    No
  • New Molecular Entity Yes

Highest Development Phases

  • Discontinued Malignant melanoma; Non-Hodgkin's lymphoma; Non-small cell lung cancer; Solid tumours

Most Recent Events

  • 30 Nov 2013 Phase-II clinical trials in Malignant melanoma (second-line therapy or greater, late-stage disease) in USA (IV)
  • 25 Oct 2013 EMD Serono plans a phase IIa trial for Malignant melanoma (unresectable or metastatic disease) in USA (NCT01973608)
  • 31 Jan 2012 Merck completes a phase I trial in Non-Hodgkin's lymphoma and Solid tumours in Germany and Switzerland (NCT00879866)
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top